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Abstract
Purpose: Pancreatic ductal adenocarcinoma (PDAC) is largely incurable due to
late diagnosis. Superior early detection biomarkers are critical to improving PDAC
survival and risk stratification.
Experimental Design: Optimized meta-analysis of PDAC transcriptome datasets
identified and validated key PDAC biomarkers. PDAC-specific expression of a 5-gene
biomarker panel was measured by qRT-PCR in microdissected patient-derived FFPE
tissues. Cell-based assays assessed impact of two of these biomarkers, TMPRSS4 and
ECT2, on PDAC cells.
Results: A 5-gene PDAC classifier (TMPRSS4, AHNAK2, POSTN, ECT2, SERPINB5)
achieved on average 95% sensitivity and 89% specificity in discriminating PDAC from
non-tumor samples in four training sets and similar performance (sensitivity = 94%,
specificity = 89.6%) in five independent validation datasets. This classifier accurately
discriminated PDAC from chronic pancreatitis (AUC = 0.83), other cancers (AUC =
0.89), and non-tumor from PDAC precursors (AUC = 0.92) in three independent
datasets. Importantly, the classifier distinguished PanIN from healthy pancreas in
the PDX1-Cre;LSL-KrasG12D PDAC mouse model. Discriminatory expression of the PDAC
classifier genes was confirmed in microdissected FFPE samples of PDAC and matched
surrounding non-tumor pancreas or pancreatitis. Notably, knock-down of TMPRSS4
and ECT2 reduced PDAC soft agar growth and cell viability and TMPRSS4 knockdown
also blocked PDAC migration and invasion.
Conclusions: This study identified and validated a highly accurate 5-gene PDAC
classifier for discriminating PDAC and early precursor lesions from non-malignant
tissue that may facilitate early diagnosis and risk stratification upon validation in
prospective clinical trials. Cell-based experiments of two overexpressed proteins
encoded by the panel, TMPRSS4 and ECT2, suggest a causal link to PDAC development
and progression, confirming them as potential therapeutic targets.
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Introduction

[9, 10]. The relevance of these genes for PDAC remains
unclear due to inherent statistical limitations of the
applied approaches combined with batch effects, variable
techniques and platforms, and varying analytic methods
[11]. Lack of concordance of published gene signatures
of individual microarray studies due to variability in
analytical strategies makes comparative analysis difficult
when standard approaches are used [11].
One alternative to overcome the limitations of
analyzing individual microarray datasets or multiple
datasets that have been processed and normalized
by different approaches is meta-analysis of multiple
transcriptional profiling studies applying identical
analytics that can generate gene signatures with increased
reproducibility and sensitivity, revealing biological insight
not evident in the original datasets [12]. The increased
statistical power of this approach may identify a more
reliable transcriptome signature by detecting potentially
important genes missed in a single study or in an analysis
of multiple studies using divergent analytical methods
and eliminating false positives [11]. We now report the
identification of a 5-gene PDAC classifier based on our
meta-analysis of publicly available PDAC microarray
datasets that accurately discriminates PDAC and early
PDAC precursors from benign pancreatic lesions and
healthy controls. We demonstrate validation of these 5
genes as PDAC-specific in FFPE samples from patients
with PDAC, providing strong support for the predicted
diagnostic performance of our 5-gene PDAC classifier.

Pancreatic ductal adenocarcinoma (PDAC), the third
leading cause of cancer death in the United States (US),
is marked by an exceptionally high mortality rate [1],
due to late diagnosis when curative resection is no longer
possible. Although imaging and endoscopic approaches
assist with PDAC staging, their efficacy is limited for
screening and risk stratification, and PDAC diagnosis
can be limited by indeterminate pathologic evaluation
of biopsy specimens [2]. Therefore, superior biomarkers
for earlier detection of PDAC and for improved risk
stratification are imperative for improving PDAC survival.
The magnitude of the need for better PDAC
biomarkers is large: 330,000 patients worldwide die
from PDAC annually and many must face uncertainty of
diagnostic tests or the malignant potential of incidentally
discovered pancreatic lesions and PDAC risk factors. For
example, the limits of cytologic examination of pancreatic
mass lesions often preclude definitive diagnosis of PDAC,
particularly in the presence of chronic pancreatitis and
when an on-site cytopathologist is not available [3, 4].
Moreover, rapid improvements in imaging quality and the
number of imaging procedures (26 million annually in the
US) have led to a rise in identification of potential PDAC
precursor lesions such as intraductal papillary mucinous
neoplasms (IPMNs) and mucinous cystic neoplasms
(MCNs). Although resection of precursor lesions is
associated with better survival, it is often uncertain which
lesions will progress to invasive cancer and morbidity and
mortality of surgery can be high [5]. Accurate biomarkers
to aid risk stratification would greatly improve the current
diagnostic and decision-making quandary for these
patients. Similarly, accurate biomarkers are greatly needed
to improve screening, particularly for those who may be
at increased risk of developing PDAC: family history of
PDAC, hereditary syndromes, chronic pancreatitis, type 3c
diabetes, smokers, BRCA2 carriers, etc. [6].
Several serum-based (CA19-9, CA125) and tissuespecific (macrophage inhibitory cytokine-1, K-ras,
mesothelin, PSCA, mucins, SMAD4, p53 mutations)
proteins have been tested as potential PDAC diagnostic
biomarkers. All have failed to demonstrate the accuracy
needed for early detection or screening [7]. CA19-9 is
used clinically to monitor PDAC response to therapy, but
its utility for screening and risk-assessment is limited: it
can be elevated in benign intra-abdominal processes and
normal when PDAC tumors are small, the time when
resolving diagnostic uncertainty is most important [8].
The urgent need for improved PDAC diagnosis
has spurred a number of studies aimed at identifying
differentially expressed genes in PDAC. However, no
transcriptome data has yet translated into a clinically
useful biomarker. Integration of the literature on
candidate PDAC biomarkers resulted in identification of
several thousand differentially expressed PDAC genes
www.impactjournals.com/oncotarget

Results
Dataset identification and meta-analysis strategy
To identify biomarkers that accurately discriminate
between PDAC and normal pancreas or benign pancreatic
lesions, we selected publicly available transcriptional
profiling datasets for meta-analysis. These datasets were
divided into training sets for development of a PDAC
biomarker classifier and independent validation sets (see
overview of meta-analysis strategy in Figure 1).
Among the publicly available microarray
repositories, we selected four transcriptional profiling
datasets of normal pancreas and PDAC tissue samples
as training sets (Figure 1 and Table 1A), including
two datasets from microdissected pancreatic tissue
(GSE18670: 6 normal, 6 PDAC; E-MEXP-950: 9
normal, 13 PDAC) and two datasets from whole tissue
(GSE15471: 35 normal, 35 PDAC; GSE16515: 14
normal, 36 PDAC) (Table 1A). In Phase I of independent
validation, performance of the optimized PDAC biomarker
panel was validated on five additional datasets (Table 1B).
Phase I Validation was restricted to Affymetrix datasets
from clinical samples similar to the training sets, namely
23264
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Table 1A: Datasets used for development of PDAC classifier
Training Sets:
Dataset

Normal

Tumor

Sample Type

Platform

Accession #

Set1

6

6

Enriched

U133 Plus 2.0

GSE18670

Set2

9

13

Microdissected

U133A

E-MEXP-950

Set3

35

35

Whole Tissue

Plus 2.0

GSE15471

Set4

14

36

Whole Tissue

Plus 2.0

GSE16515

Number of samples reflects only the samples that were used for the meta-analysis, after removing samples with low quality,
outlier arrays.
Table 1B: Datasets used for independent validation of PDAC classifier
Phase I Validation Sets:
Dataset

Normal

Tumor

Sample Type

Platform

Accession #

V1

7

25

Whole Tissue

Plus 2.0

GSE32676

V2

45

45

Whole Tissue

Gene St 1.0

GSE28735

V3

0

36

Whole Tissue
(Xenografts in duplicate)

Plus 2.0

GSE9599

V4

0

18

Microdissected

Plus 2.0

E-MEXP-2894

V5

145

0

Whole Tissue & Cell Lines U133A
(most 3 replicates)

E-TABM-145

Phase II Validation Sets:
Dataset

Group

Pancreatic Tumor

Sample Type

Platform

Accession #

P1

6 (Normal)

15 (IPMA, IPMC, IPMN)

Microdissected

Plus 2.0

GSE19650

P2

9 (Pancreatitis)

6

Microdissected

U133A

E-MEXP-1121

C1
M1

4 (Normal)
25 (other Cancers)

28
11

Whole Tissue
Whole Tissue

Agilent
U133A

GSE11838
GSE12630

comparison of normal versus PDAC samples (two datasets:
GSE32676: 7 normal, 25 PDAC; GSE28735: 45 normal,
45 PDAC), only PDAC samples (2 datasets: GSE9599:
36 PDAC; E-MEXP-2894: 18 PDAC) and only normal
pancreas tissue (1 dataset: E-TABM-145: 145 normal). In
Phase II Validation, PDAC biomarker panel performance
was tested on four additional independent datasets
that compared results from: i) PDAC versus normal
www.impactjournals.com/oncotarget

pancreatic tissue on Agilent microarrays (GSE11838:
4 normal, 28 PDAC), ii) PDAC versus other cancers
(breast, colon, liver, lung, prostate) (GSE12630: 25 other
cancers, 11 PDAC), iii) PDAC versus chronic pancreatitis
(E-MEXP-1121: 9 pancreatitis, 6 PDAC), and iv) normal
pancreas versus PDAC precursor lesions (IPMN with lowto intermediate-grade dysplasia (LIGD-IPMN, previously
called intraductal papillary-mucinous adenoma (IPMA)),
23265
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Figure 1: Overview of meta-analysis approach for development and validation of PDAC biomarker biomarker panel.
www.impactjournals.com/oncotarget
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IPMN with high-grade dysplasia (HGD-IPMN, previously
called intraductal papillary-mucinous carcinoma (IPMC))
and IPMN with associated invasive carcinoma (InvCaIPMN, previously called invasive cancer originating from
IPMN) (GSE19650: 6 normal, 15 PDAC precursors (5

LIGD-IPMN, 5 HGD-IPMN, 5 InvCa-IPMN)) (Figure
1 and Table 1B). All datasets utilized oligonucleotidebased microarray platforms (three versions of Affymetrix
GeneChips and Agilent microarrays in one dataset).

Figure 2: Meta-signature of genes that are consistently differentially expressed in multiple datasets and candidate
PDAC diagnostic biomarker panels. A. Signal to Noise ratio based heatmap of the 409 meta-signature genes. B. Description of the

genes from the 5- and 10-gene based PDAC biomarker panels. C. Relative expression of the 10 candidate biomarker genes across all four
training sets visualized as a heatmap.
www.impactjournals.com/oncotarget
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Identification of PDAC biomarker candidates

to normal pancreas across most of the samples.
We performed LOOCV of the 10-gene and 5-gene
PDAC classifier across the four training datasets in order
to compare predictive performance and to determine
which of these two classifiers to further evaluate on the
independent test sets. LOOCV of the 5-gene classifier
demonstrated overall better performance than the 10gene predictor for the four training sets. While for each
of the four training datasets individually sensitivity ranges
from 0.89-1.0 and specificity from 0.80-1.00 for the
5-gene predictor (Figure 3A), for the 10-gene predictor
sensitivity ranges from 0.77-1.0 and specificity from
0.67-1.00 (Figure 3B). Comparison of the 5- and 10-gene
PDAC classifier performance shows an average 0.95
sensitivity and 0.89 specificity for the 5-gene classifier,
in contrast to 0.89 sensitivity and 0.83 specificity for the
10-gene classifier (Figure 3C). Based on this comparison
of the 10-gene PDAC classifier to the 5-gene classifier,
only the 5-gene classifier was further evaluated on the
independent datasets. Random sampling based ROC
prediction across the training sets further confirms that
the 5-gene PDAC predictor has indeed the largest AUC
(Figure 3D): AUC for the four datasets ranged from 0.881.0 with median=0.93 (Figure 3E, demonstrates threshold
independent performance).
Evaluation of the GENT database that compares
relative expression of genes between different cancers and
their normal tissue counterparts indicates that all genes in
the 5-gene classifier are overexpressed in PDAC relative
to normal pancreas (Supplementary Figure S3). Each of
these 5 genes appears also overexpressed in several other
types of cancer (Supplementary Figure S3).

Using identical normalization and statistical
methods for each dataset, a broad range of differentially
expressed genes was identified through empirical Bayes
comparative meta-analysis of the raw expression data
in the four PDAC training datasets. The number of
differentially expressed genes ranged from 90 to 10,169
genes (See Supplementary Table S1), totaling 11,322
significantly differentially expressed genes in the four
training datasets. Heatmaps for the top up- and downregulated genes in two of the datasets are shown in
Supplementary Figure S1A. Venn diagram analysis of
these differentially expressed genes identified 409 genes
with concordant directionality to at least three of the four
datasets (Supplementary Figure S1B). These 409 genes
were selected for further evaluation.
Consistent expression across these four datasets for
each of the 409 concordant genes is demonstrated in a
heatmap of the relative ratio of gene expression in PDAC
compared to normal pancreas (NP) (Figure 2A), with the
extent of overexpression or underexpression denoted by
red or blue shading, respectively. Principal Component
Analysis (PCA) of these 409 genes shows a dominant
separation pattern for most of the PDAC and normal
pancreas samples in each dataset (Supplementary Figure
S1C).
Canonical pathway analysis of these 409 common
PDAC genes using Ingenuity Pathway Analysis identified
the highest statistical enrichment of these genes in various
cancer-related pathways linked to DNA damage (ATM
Signaling, DNA damage-induced 14-3-3σ Signaling,
GADD45 signaling), cell cycle (G2/M DNA damage
checkpoint regulation, Cell cycle control of chromosomal
replication, p53 signaling, Mitotic role of Polo-like
kinase), and Protein kinase A signaling (Supplementary
Figure S2). Most of these pathways play important roles
in PDAC.

The 5-gene PDAC classifier predicts PDAC with
high accuracy in 9 independent validation sets
In Phase I Validation, the 5-gene PDAC classifier
accurately predicted the class of PDAC compared to
NP with a sensitivity of 96% and 88.89%, a specificity
of 85.7 and 86.67%, and AUC of 0.9 and 0.8778 in two
independent validation sets that contained 25 and 45
PDAC and 7 and 45 normal pancreas samples, respectively
(Figure 4A and Table 1B). These results are significantly
better than various published values for CA19-9 [13, 14].
In two datasets containing exclusively PDAC samples a
sensitivity of 97.22% and 94.5% was achieved and in a
dataset containing 145 normal samples a specificity of
96.5% was determined.
In Phase II Validation, we tested the 5-gene PDAC
classifier on a dataset that includes 6 PDAC samples and
9 chronic pancreatitis samples (Table 1B). Specificity was
88.9% and sensitivity 100% with an overall accuracy of
80% and an AUC of 0.83 (Figure 4B, Left Graph). Since
discrimination between chronic pancreatitis and PDAC is
a key clinical challenge, the fact that the 5-gene PDAC

Class prediction analysis in training sets
Class prediction analysis with support vector
machines generated a large number of PDAC classifiers
containing 2 to 40 genes. Based on LOOCV evaluation
in the training sets, classifiers containing 5 or 10 genes
performed with highest accuracy. The 5-gene PDAC
classifier (TMPRSS4, ECT2, SERPINB5, AHNAK2,
POSTN) is a subset of the 10-gene PDAC classifier
(TMPRSS4, ECT2, SERPINB5, AHNAK2, POSTN,
S100P, CEACAM5, GABRP, CELA2B, CUZD1) and
only includes genes overexpressed in PDAC (Figure 2B).
The 10-gene PDAC classifier includes 2 genes (CELA2B,
CUZD1) that are reduced specifically in PDAC. A heatmap
of these 10 genes across the four training sets (Figure 2C)
demonstrates differential expression in PDAC compared
www.impactjournals.com/oncotarget
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Figure 3: Performance of 5-gene and 10-gene PDAC Classifiers on training sets using leave one out cross-validation
(LOOCV). A. Diagnostic performance of the 5-gene PDAC classifier on the four training sets of PDAC vs. normal pancreas. Sensitivity

(Sens.) and specificity (Spec.) are indicated below each set. B. Diagnostic performance of the 10-gene PDAC classifier on the four
training sets of PDAC vs. normal pancreas. Sensitivity (Sens.) and specificity (Spec.) are indicated below each set. C. Comparison of the
performance of the 5- and 10-gene PDAC classifiers across the four training sets. D. AUC curve for random sampling based prediction.
The ranking of the 5-gene PDAC classifier is indicated. E. AUC plot for 5-gene PDAC classifier across the four training sets and for the
median of the four datasets.
www.impactjournals.com/oncotarget
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classifier accurately distinguishes between PDAC and
pancreatitis is a further important validation step for this
5-gene biomarker panel. We similarly tested the 5-gene
PDAC classifier on an independent validation dataset
containing laser microdissected normal main pancreatic
duct epithelial cells and neoplastic epithelial cells from
potential PDAC precursor lesions, LIGD-IPMN, HGDIPMN and InvCa-IPMN [15]. The 5-gene predictor
separated LIGD-IPMN, HGD-IPMN and InvCa-IPMN
from normal pancreatic duct epithelial cells with 100%
sensitivity and 83% specificity, achieving an AUC of 0.92
(Figure 4B, Right Graph). The ROC curves for normal
vs. PDAC, chronic pancreatitis vs. PDAC, and normal vs.
LIGD-IPMN, HGD-IPMN, and InvCa-IPMN are shown
in Figure 4C.
Hierarchical clustering of this dataset demonstrates
that the 5-gene PDAC classifier separates all potential
PDAC precursor (LIGD-IPMN, HGD-IPMN, InvCaIPMN) samples from the normal pancreatic duct samples
except for one normal sample (Figure 4D, Left Heatmap).
Four classifier genes are consistently overexpressed in the
PDAC precursor samples. TMPRSS4 and SERPINB5 are
increased relative to 6 of the 7 normal pancreas samples
in 100% of the PDAC precursor samples. AHNAK2 is
elevated in 87% and ECT2 in 80% of the PDAC precursor
samples. POSTN was not differentially expressed, but its
expression had little impact on overall performance of the
classifier in this dataset.
Applying the 5-gene classifier to a dataset that
included 11 PDAC samples and 25 tumor samples of
various origins (breast, colon, liver, lung, prostate)
resulted in sensitivity of 72.73% and specificity of 96%
(Supplementary Figure S4A). The ROC curve is shown
in Supplementary Figure S4A. These results suggest that
the 5-gene classifier not only discriminates PDAC and its
precursors from normal pancreas and benign pancreatic
lesions, but also from several other types of cancer.
While all datasets analyzed above were derived
on the Affymetrix platform, one small dataset on the
Agilent microarray platform was available (GSE11838).
Cross-platform evaluation on this dataset of PDAC versus
normal pancreas demonstrated a sensitivity and specificity
of 96.4% and 75% respectively and an AUC of 0.84
(Supplementary Figure S4B).

mutant Kras GEM models exist that spontaneously
develop PDAC through the stages of PanIN development
[17]. One GEM PDAC model is the PDX1-Cre;LSLKrasG12D model [17]. These mice develop low and highgrade progressive ductal PanIN lesions with increasing
age and low frequency progression to invasive PDAC
upon activation of oncogenic Kras in the pancreas,
phenocopying development of human PDAC [17, 18]. We
applied an unsupervised learning approach, hierarchical
clustering, to one available Affymetrix microarray dataset
of three biological replicates each of normal pancreatic
tissue, PanIN and PDAC from the PDX1-Cre;LSLKrasG12D mice using the expression values of our five
PDAC classifier genes [18]. Hierarchical clustering of this
dataset using the equivalent mouse GeneIDs demonstrated
that all 5 genes were upregulated in both PanINs and
PDAC compared to normal pancreas, resulting in perfect
separation of PanINs and PDAC samples from normal
pancreas (Figure 4D, Right Heatmap). Interestingly,
PanINs perfectly separated from PDAC. PanIN samples
clustered on the same main branch as the normal pancreas,
but on a separate subbranch within this tree, suggesting
that PanIN is indeed a stage different from normal, but in
between normal and PDAC. POSTN exhibited the same
level of overexpression in PanIN and PDAC compared
to normal pancreas, TMPRSS4 was higher expressed in
PanIN than PDAC, and ECT2, AHNAK2, and SERPINB5
were higher expressed in PDAC (Figure 4D, Right
Heatmap). These results provide the strongest evidence
that the 5-gene PDAC classifier is able to discriminate
early PDAC precursor lesions from normal pancreas
and that differential expression of these 5 genes may
even differentiate between PanIN and PDAC, suggesting
dynamic, malignancy-related changes of these 5 genes
during PDAC development.

qRT-PCR validation of the 5-gene PDAC
classifier in retrospective FFPE patient samples
demonstrates overexpression of the 5 genes in
PDAC as compared to pancreatitis or healthy
pancreas
To determine whether the five PDAC classifier
genes indeed are higher expressed in PDAC than normal
pancreas or benign pancreatic lesions, we developed
a qRT-PCR assay for the five genes and evaluated the
expression pattern of the 5-gene PDAC classifier in 22
microdissected paired retrospective FFPE patient samples
containing PDAC and matched non-tumor normal
pancreatic tissue (9 samples) or matched pancreatitis
tissue (13 samples) (Figure 5). Relative quantity (RQ)
values were calculated by using the matched normal or
pancreatitis tissue as the baseline to reflect the fold change
in tumor samples. In all 22 matched pairs at least 4 of
the 5 genes were elevated in pancreatic tumor tissue as

The 5-gene PDAC classifier distinguishes between
PDAC or early stage PDAC, PanIN, and healthy
pancreas in the PDX1-Cre;LSL-KrasG12D GEM
model of PDAC
While IPMNs have the potential to become
malignant and progress towards PDAC, the majority of
PDAC cases likely evolve from pancreatic intraepithelial
neoplasia [PanIN] lesions containing Kras mutations [16].
While PanINs are difficult to detect in humans, various
www.impactjournals.com/oncotarget
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Figure 4: Performance and expression of 5-gene PDAC classifier on independent validation sets. A. Diagnostic performance
of 5-gene PDAC classifier on five independent validation sets of normal and PDAC tissue samples. PPV = positive predictive value, NPV =
negative predictive value. B. Diagnostic performance of the 5-gene PDAC classifier on Pancreatitis vs. Pancreatic Cancer dataset (Left) and
on a dataset of normal pancreatic duct compared to LIGD-IPMN, HGD-IPMN, and InvCa-IPMN (Right). C. ROC curves for the different
independent validation datasets. D. Hierarchical clustering analysis showing performance and expression of the 5-gene PDAC classifier on
normal pancreatic duct compared to LIGD-IPMN, HGD-IPMN, and InvCa-IPMN samples. Red = upregulated, Blue = downregulated (Left
Heatmap). Cross-species performance of the 5-gene PDAC classifier on a GEM mouse model of PDAC (Right Heatmap). Hierarchical
clustering of pancreatic tissue samples from three mice each for normal pancreas, PanIN and PDAC across the 5-gene PDAC panel. Red
= upregulated, Blue = downregulated.
www.impactjournals.com/oncotarget
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compared to normal or pancreatitis tissue, and the box plots
reflecting the relative expression of each gene compared
to either matched normal or pancreatitis demonstrate
clear discrimination, providing strong support that these
5 genes are selectively overexpressed in PDAC (Figure
5). Most importantly, this differential expression of the 5
genes was validated in PDAC compared to pancreatitis,
a clinically highly relevant differential diagnosis. All five
genes showed elevated average expression in PDAC tissue
compared to normal pancreas or pancreatitis tissue. The
degree of upregulation when compared to normal tissue

was significantly higher in three (POSTN, SERPINB5,
TMPRSS4) of five genes than compared to pancreatitis,
suggesting that POSTN, SERPINB5 and TMPRSS4
expression increase gradually from healthy pancreas to
pancreatitis to PDAC. AHNAK2 and ECT2 also showed
elevated levels of expression in the matched PDAC tissue
compared to normal or pancreatitis (fold change ~5-8),
but the levels of these fold changes relative to normal and
pancreatitis tissues were not significantly different.

Figure 5: qRT-PCR validation of 5-gene PDAC classifier on retrospective microdissected FFPE samples from patients
with PDAC. Total RNA was isolated from 22 matched pairs of PDAC and pancreatitis (n = 13) or healthy pancreas (n = 9). FFPE tissue

blocks were inspected by the pathologist and marked regions of PDAC, pancreatitis and healthy pancreas microdissected. QRTPCR was
performed on each sample for POSTN, SERPINB5, AHNAK2, TMPRSS4 and ECT2 in duplicates. Box plots of fold change (RQ values)
of PDAC samples relative to their matched pancreatitis or normal pancreas samples after normalization to GAPDH are shown. Average
fold change values for each gene when the baseline was pancreatitis or normal tissue are indicated separately for each box plot. For each
gene the ratio of the average fold change values for PDAC vs. pancreatitis or normal pancreas when the baseline was normal vs. pancreatitis
tissue is indicated above the lines along with the statistical significance of the fold change value distributions in PDAC vs. normal or
pancreatitis (**:p < 0.05, ns:non-significant).
www.impactjournals.com/oncotarget
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TMPRSS4 knockdown decreases PDAC cell
migration, invasion, and anchorage-independent
growth

and progression, we selected two of the genes, TMPRSS4,
that has been previously linked to PDAC and other types of
cancer [19-25] and ECT2, an oncogene that has previously
been shown to be overexpressed in PDAC and other types
of cancer [26]. TMPRSS4 protein expression in PDAC
has not previously been studied. Western blot analysis

To evaluate whether the PDAC classifier encodes
proteins that are causally related to PDAC development

Figure 6: Verification of TMPRSS4 function in various PDAC cells. A. TMPRSS4 protein expression across various PDAC cell

lines and HPDE cells. Western Blot analysis of TMPRSS4 and beta actin. B. Cell viability of TMPRSS4 knockdown cells. Western Blot
analysis of TMPRSS4 in whole cell lysates from BxPC-3 and Capan-1 cells 72 hours after shTMPRSS4 or shGFP infection (Top). Cell
viability analysis of parental cells, shTMPRSS4 and shGFP cells using MTS assay (Bottom). C. + D. Knockdown of TMPRSS4 reduces
migration and invasion of PDAC cells. Capan-1 cells or BxPC-3 cells stably transfected with shGFP-treated cells (control shRNA) or
TMPRSS4 shRNA were placed in serum-free culture media and added into the upper compartment of a migration or invasion chamber.
After 16 hours, cells in the upper chamber were removed and cells that had migrated or invaded through the pores of the membrane to the
other side were fixed, stained, and counted. Cells in five different areas were quantified for migration and invasion studies. C, quantification
of cells migrating through fibronectin-coated membranes. D, quantification of cells invading through Matrigel-coated membranes after
16-h incubation and 10% serum as chemoattractant.

www.impactjournals.com/oncotarget
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a 5-gene PDAC classifier that differentially diagnoses
PDAC and precursor lesions with high accuracy. This
5-gene PDAC classifier was validated in 9 independent
human datasets, one dataset derived from a GEM mouse
model of PDAC and by retrospective qRT-PCR analysis
of patient-derived FFPE tissue samples. Most importantly,
this 5-gene PDAC classifier discriminates between PDAC
and pancreatitis and between PDAC precursor lesions
and healthy pancreas. The 5-gene PDAC classifier
encodes proteins involved in PDAC pathogenesis, such as
TMPRSS4 and ECT2, that are overexpressed even at the
earliest stages of PDAC development, suggesting causality
during early PDAC development.
The 5-gene PDAC classifier performed well
across multiple microarray platforms from different
laboratories and cross-species, using either whole tissue
or microdissected tissue. While over 2500 candidate
biomarkers have been associated with PDAC and some of
these candidates are in various stages of evaluation, only
CA19-9 is FDA-approved for PDAC [28]. Nevertheless,
CA19-9 does not provide an accuracy high enough
for screening, particularly for early detection or risk
assessment. Currently, no diagnostic or predictive gene or
protein expression biomarkers that accurately discriminate
between healthy patients, benign, premalignant and
malignant disease have been extensively validated. The
goal of this study was to identify a biomarker panel with
greater sensitivity and specificity compared to the primary
biomarker currently used for PDAC, CA19-9. Our data
suggest that a multiplex panel of biomarkers, rather than a
single biomarker, is more likely to improve the specificity
and selectivity for accurate detection of PDAC. Compared
to the sensitivity of 79-81% and specificity of 82-90% for
CA19-9 the sensitivity of our 5-gene PDAC classifier is
superior [>85%] and with equal or better specificity [29].
We converted the in silico validation of publicly
available transcriptome datasets into a qRT-PCR based
assay for FFPE samples and confirmed in 22 pairs of
retrospective patient samples that the 5-gene panel clearly
discriminates between PDAC and pancreatitis or healthy
pancreas. Importantly, expression of three of the five
genes, POSTN, SERPINB5 and TMPRSS4, apparently
increases gradually from healthy pancreas to pancreatitis
and further rises between pancreatitis and PDAC. These
three genes, thus, may reflect different pathophysiological
functions from the two genes, AHNAK2 and ECT2 that
are increased to a similar degree in PDAC when compared
to pancreatitis or healthy pancreas. Differential diagnosis
between PDAC and pancreatitis is critical, since patients
with chronic pancreatitis are at increased risk of PDAC
development and pathological discrimination between
PDAC and pancreatitis can be challenging for definitive
diagnosis of PDAC. Recent advances in endoscopic
ultrasound (EUS) have yielded improved sensitivity
for PDAC identification. Nevertheless, differentiating
between PDAC and benign disease remains operator-

verified increased TMPRSS4 protein expression in several
PDAC cell lines compared to an immortalized pancreatic
epithelial cell line, HPDE (Figure 6A). Particularly high
TMPRSS4 expression was observed in MIA PaCa-2,
Panc-1, Capan-1 and BxPC-3 PDAC cells. The functional
relevance of TMPRSS4 or ECT2 in PDAC cells has not
previously been determined, although TMPRSS4 has
been demonstrated to induce invasion and epithelial-tomesenchymal transition ( EMT) of colorectal cancer cells
[24, 25] and ECT2 overexpression has been primarily
linked to cell proliferation, invasion and migration in
lung cancer or glioma cells [26]. We infected two PDAC
cell lines (Capan-1, BxPC-3) expressing high levels of
TMPRSS4 with lentiviral vectors expressing shRNAs
against TMPRSS4 (shTMPRSS4) or lentivirus expressing
shGFP and Capan-1 cells with lentiviral vectors expressing
shECT2 or scrambled shRNA. ShTMPRSS4 knocked
down TMPRSS4 protein expression by more than 80% in
both cell lines without affecting β-actin expression (Figure
6B). TMPRSS4 knock-down decreased cell viability, as
measured with the MTS assay, in Capan-1 and BxPC-3
cells (Figure 6B). Similar to TMPRSS4, ECT2 knockdown significantly decreased cell viability in Capan-1
cells (Supplementary Figure S6A).
TMPRSS4 knockdown reduced serum-induced
migration of Capan-1 and BxPC-3 cells through the
pores in a Transwell chamber assay by more than 80%
compared with shGFP cells (Figure 6C). Because cell
migration promotes tumor invasion, we tested the effect
of TMPRSS4 knockdown on cell invasion using Matrigelcoated Transwell chambers. TMPRSS4 knockdown
compared with shGFP decreased Capan-1 and BxPC3 invasion by 60-90% after 16-h incubation (Figure
6D). In contrast, knockdown of ECT2 did not have any
significant effect on migration or invasion of Capan-1
cells (Supplementary Figure S6C and D). These results
demonstrate that TMPRSS4, but not ECT2 is an inducer
of PDAC cell migration and invasion.
One of the hallmarks of malignancy is loss of
anchorage-dependent growth as demonstrated by the
ability to form colonies in soft agar. TMPRSS4 and
ECT2 knockdown in PDAC cells significantly reduced
anchorage-independent growth compared with the shGFP
and parental cells in soft agar assays (Supplementary
Figures. S5 and S6B). These results suggest that the
5-gene PDAC classifier includes genes that are directly
implicated in pathophysiological mechanisms of PDAC.

Discussion
We applied an innovative data mining approach
to multiple transcriptome datasets followed by class
prediction analysis and validation in independent datasets
to discover candidate PDAC biomarkers [9, 27]. We
identified a 10-gene and, as the most parsimonious and best
performing panel and a subset of the 10-gene classifier,
www.impactjournals.com/oncotarget
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IPMN with associated invasive carcinoma from healthy
pancreas. In this context it is reassuring to observe that
the 5-gene PDAC classifier performs equally well in the
PDX1-Cre;LSL-KrasG12D mouse model of PDAC that
phenocopies the human disease and allows evaluation of
the different developmental stages of PDAC development,
including PanIN, that are typically not detected and
sampled in humans [37]. We discovered that all 5 genes
are overexpressed already in PanIN, indicating that
these 5 genes become dysregulated very early during
PDAC development and could indeed assist in early
detection of PDAC. IPMNs and other pancreatic cysts
are frequent events in older patients (in some autopsy
studies up to 24%). Imaging improvements have resulted
in an increasing number of asymptomatic, incidentally
discovered pancreatic cysts [38]. While many are benign,
MCNs and IPMNs have a significant incidence (2.413.5%) of either harboring malignant cells or progressing
towards invasive cancer [39]. Consequently, pancreatic
cysts cannot be ignored; however, current diagnostic
tools are limited for accurately predicting their malignant
potential. Survival upon surgical resection of nonmalignant lesions is close to 100% and after malignant
transformation drops to 55-60% [40]. Resection of all
pancreatic cysts is difficult due to relatively high rates
of mortality (1-6%) and morbidity (35-51%) in elderly
patients. A key challenge is how to prioritize the cysts that
can be ignored or followed versus the ones that should
be surgically resected. An early detection marker, one
able to detect PDAC precursor lesions (IPMN, PanIN)
with early malignant transformation or high risk for
malignant transformation, would increase the likelihood
of identifying such patients that may have localized
disease amendable to curative surgery. Better diagnosis
of borderline and invasive IPMNs and MCNs would
be highly significant, and enable patients to choose the
most appropriate course of action; this 5-gene PDAC
classifier may provide such a risk assessment. Discovery
and validation of a distinct set of sensitive and specific
biomarkers for risk-stratifying patients at high risk for
developing PDAC would eventually enable routine
screening of high risk groups (i.e., incidental detection
of pancreatic lesions, family history of PDAC, hereditary
syndromes (VHL), chronic pancreatitis, type 3c diabetes,
smokers, BRCA2 carriers, etc).
While other studies have performed meta-analysis
of transcriptome data for PDAC, such as a recent metaanalysis study that identified more than 800 genes that
are overexpressed in PDAC [41], none of these studies
including this latest report attempted to select any
genes as PDAC predictors. In contrast, there has been
significant progress in identifying circulating miRNAs
that distinguish PDAC from chronic pancreatitis and
healthy patients in plasma and bile [42]. A 5 miRNA panel
diagnosed PDAC with 95% sensitivity and specificity
in a cohort that included healthy, chronic pancreatitis

dependent and sometimes challenging, frequently
requiring multiple biopsies and procedures. Even after
two EUS fine needle aspiration (FNA) biopsy procedures,
diagnosis remains ambiguous for a subset of patients with
a pancreatic abnormality [30], particularly in the setting of
pancreatitis. This may result in diagnostic uncertainty and
delays in potentially curative treatment. Thus, a key unmet
medical need with immediate clinical utility is an effective
cell-based diagnostic test that accurately differentiates
between PDAC and non-malignant pancreatic disorders
such as chronic pancreatitis.
Pre-operative diagnosis of pancreatic cancer is often
limited by the performance of Endoscopic ultrasoundguided fine-needle aspiration (EUS-FNA), a common
diagnostic approach that may be inconclusive in up to
20% of cases and for which inter-observer reliability is
suboptimal even for biopsy evaluation [31-36]. More
specifically, a wide range of performance parameters have
been reported for malignancy diagnosis on cytopathologic
analysis of EUS FNA: sensitivity from 73% to 94%,
accuracy from 78% to 95% and a negative predictive value
from 40% to 85% when specificity approaches 100% [3136]. Therefore, improved performance for the diagnosis
of pancreatic lesions on aspiration or biopsy tissue is
critical to early and effective treatment. The 5-gene PDAC
classifier described in this manuscript may be first applied
as a FNA-based real time PCR test to complement the
pathologist and enhance positive and negative predictive
value in diagnosing pancreatic cancer and differential
diagnosis.
Moreover, due to widespread use of abdominal
cross-sectional imaging, pancreatic cysts are detected
in ~2% of all patients who undergo abdominal imaging
with computed tomography and ~15% of all patients who
undergo an abdominal MRI. Once imaged, pancreatic
cysts are frequently biopsied and classified as PanINs,
MCNs and IPMNs. However, the guidelines with regards
to monitoring and treatment of these cystic lesions remain
unclear and no definitive diagnosis about malignancy or
risk of malignancy can be made.
Frequently, EUS combined with FNA is used to
visualize the pancreas from the duodenum or stomach
but is sometimes challenged with diagnostic accuracy in
detecting malignant lesions under 3 cm even by skilled
clinicians. However, EUS-FNA has less than optimal
accuracy for differentiating pancreatic cancer from chronic
pancreatitis. Since only a small minority of these cysts, but
still significant number, subsequently progress to cancer,
there may be needless over- or under-treatment, and
morbidity. Our 5-gene classifier may be able to be applied
in the setting where FNAs are taken from cysts or other
suspicious pancreatic lesions for differential diagnosis.
Above all, the 5-gene PDAC classifier accurately
distinguishes premalignant and malignant pancreatic
lesions such as PanIN, IPMN with low- to intermediate
grade dysplasia, IPMN with high-grade dysplasia and
www.impactjournals.com/oncotarget
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and PDAC patients [42]. However, there is no evidence
whether these miRNAs would diagnose early stages of
PDAC.
The set of PDAC biomarkers identified in this study
may be regulated by a common set of upstream regulatory
transcription factors. However, based on available data
and Ingenuity upstream regulator analysis no common
upstream regulator or transcription factor was identified
by us. This is no surprise, since AHNAK2 and TMPRSS4
have rather limited information available. Using the
Transfac database we have analyzed the promoter regions
between -2000 and +100 for the 5 genes for common
transcription factor binding sites. Transfac analysis
identified 6 transcription factors (ZNF333, Ikaros, ING4,
MZF-1, CRX, NF-AT1) with predicted binding sites in
4 out of the 5 genes, suggesting that these transcription
factors may be common to these PDAC classifier genes
(data not shown). Nevertheless, further studies are needed
to explore the potential role of these transcription factors
in controlling expression of these genes in PDAC.
To determine whether the set of biomarkers
encoded by our PDAC classifier may also reflect key
pathophysiological pathways associated with PDAC
development or progression that may be candidate
therapeutic targets (i.e., similar to value of Her2/neu as a
biomarker and therapeutic target), we reviewed available
public data for the classifier genes.
The 5-gene classifier includes two genes, TMPRSS4
and POSTN, previously identified as candidate PDAC
biomarkers further validating our innovative metaanalysis strategy to select significant PDAC biomarkers.
Several genes of our 5-gene classifier have been linked
to tumorigenesis, indicating a causal role in PDAC
development and progression.
Most of the classifier genes (TMPRSS4, POSTN,
SERPINB5) have been linked to migration, invasion,
adhesion and metastasis of PDAC or other cancers,
specifically associated with extracellular matrix and
tumor microenvironment. This may not be surprising
due to the dense, desmoplastic stroma associated with
PDAC that may prevent efficient drug delivery [43].
However, these biological functions would be anticipated
to be involved in PDAC progression rather than early
stages of PDAC development. To explore this aspect in
more detail we evaluated the expression levels of these
“PDAC progression” genes in the transcriptome datasets
comparing PDAC precursors (LIGD-IPMN, HGD-IPMN)
and InvCa-IPMN to normal pancreas, and PDAC vs.
PanIN vs. healthy pancreas in the GEM model) (Figure
4) [15]. TMPRSS4, SERPINB5, ECT2, and AHNAK2
are overexpressed in LIGD-IPMN, HGD-IPMN, and
InvCa-IPMN as well as in PanINs, as compared to normal
pancreas, demonstrating that enhanced expression of
multiple genes linked to metastasis and PDAC progression
occurs early on during malignant development. This
analysis indicates that the PDAC classifier may reflect
www.impactjournals.com/oncotarget

some driving early defects during PDAC development.
No details about AHNAK2 function are available,
but its closest relative AHNAK is involved in cancer
migration and EMT, providing support that AHNAK2
may elicit similar features [44]. Periostin (POSTN),
frequently overexpressed in melanoma, pancreatic,
esophageal, prostate, and liver cancer [45-47], promotes
invasiveness and metastasis of PDAC [48] and other
cancer types [49]. Maspin (SERPINB5) overexpression
correlates with increased metastasis and poor outcome
in PDAC and gastric cancer [50-52]. But SERPINB5
is regarded as a metastasis suppressor in breast and
colorectal cancer [50]. For PDAC, conflicting roles of
SERPINB5 have been described: SERPINB5-transfected
PDAC cells exhibit reduced invasive ability [53], but
SERPINB5 overexpression in PDAC is an independent
adverse prognosticator for postoperative survival [51]. The
detection of SERPINB5 in high-grade PanIN and PDAC
and its lack of expression in normal pancreatic tissues and
chronic pancreatitis suggest that SERPINB5 upregulation
occurs early during the multi-step progression of PDAC
[53, 54]. The oncogene ECT2 is overexpressed in several
cancer types including PDAC, and correlates with poor
outcome in glioma and gastric cancer [26]. We now
provide the first evidence that ECT2 may play a role in
PDAC viability and soft agar growth.
TMPRSS4, a protease of the Type II transmembrane
serine protease (TTSP) family, is highly expressed in
pancreatic, thyroid, lung, gastric, cervical, breast, and
colorectal cancer tissues and directly correlates with
poor outcome [19-25]. TMPRSS4 expression correlates
with the metastatic potential of several cancer cell lines,
and our cell-based studies demonstrate that TMPRSS4
induces migration, invasion and anchorage-independent
growth [20, 24, 25]. Moreover, we provide the first qRTPCR-based analysis for enhanced TMPRSS4 expression in
microdissected PDAC tissue as compared to pancreatitis
or healthy pancreas. TMPRSS4 promotes invasion,
migration and metastasis of colorectal and lung cancer
cells by facilitating an EMT [24, 25]. Multiple downstream
signaling pathways, including focal adhesion kinase
(FAK), extracellular signal-regulated kinase (ERK), Akt,
Src and Rac1, and integrin alpha5 expression are activated
by TMPRSS4 expression in lung and colon cancer cells
[20, 25, 55].
In conclusion, we have identified a new multiplex
panel of biomarkers for early detection of PDAC that
can be developed as a diagnostic assay, facilitating early
diagnosis and screening for malignant transition of
potential PDAC precursor lesions and for high risk patient
groups. Since the number of samples evaluated in this
study for discrimination of early stages (PanIN, IPMN
with dysplasia) of PDAC is relatively small, we will have
to further establish the accuracy on larger numbers of
such specimens. Our data combined with the supportive
published evidence suggest that the five biomarkers
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identified in our PDAC classifier can be exploited for
development of new drugs targeting these markers,
since these genes are overexpressed in precursor lesions
and have a strong rationale for involvement in PDAC
tumorigenesis and metastasis.

correction and Z-score as described in Supplementary
Material and Methods.

Materials and Methods

For training set differential expression analysis,
the two sample classes were normal pancreas (NP)
and PDAC and the null hypothesis was “no difference
in gene expression exists between the NP and PDAC
sample classes”. The differentially expressed transcripts
were identified using the linear model microarray
analysis software package (LIMMA) and on the basis of
absolute fold change of at least 1.5 and Benjamini and
Hochberg corrected p-value <.05. Differentially expressed
genes with concordant directionality (upregulation or
downregulation) in three out of four datasets were used
for training the PDAC classifier.

Meta-analysis to
biomarker panel

identify

optimal

Differential gene expression analysis

PDAC

Dataset identification
Four training sets [GSE18670, E-MEXP-950,
GSE15471, GSE16515] and nine independent validation
sets [GSE32676, GSE28735, GSE11838, GSE9599,
E-MEXP-2894,
E-TABM-145,
E-MEXP-1121,
GSE19650, GSE12630] of transcriptome data for human
pancreas specimens and one dataset of transcriptome data
from the PDX1-Cre; LSL-KrasG12D genetically engineered
mouse (GEM) model of PDAC (GSE33322) were
selected from publicly available microarray repositories
as described in Supplementary Material and Methods.

Training and independent validation of PDAC
classifier using support vector machine
The 409 genes differentially expressed in at least
3 out of 4 datasets were used for classifier generation
by implementing the Support Vector Machines (SVM)
approach using Bioconductor and using 0 as the threshold.
Classifiers were trained using normalized, preprocessed
gene expression values. Performance of classifiers in
the training sets was evaluated using internal LeaveOne-Out Cross-Validation (LOOCV). The performance
of classifiers was measured using threshold-dependent
(e.g. sensitivity, specificity, accuracy) and thresholdindependent receiver operating characteristic (ROC)
analysis. In ROC analysis, the area under the curve (AUC)
provides a single measure of overall prediction accuracy.
We developed biomarker panels ranging from 2 to 40
genes to develop highly accurate biomarker panels with a
minimum number of genes. The biomarker panel with the
highest performance in the training sets was chosen for
assessment of predictive power in 9 independent validation
datasets using threshold-dependent and -independent
(AUC) measures. For independent validation the same
threshold selected for the training set was applied.
To further compare the performance of actual
classifiers with random classifiers we performed
randomization analysis. 1000 random classifiers of
the size of actual classifiers were developed, and their
performances were compared. Statistical testing (p-value)
evaluated the hypothesis that random classifiers had the
same or better performance than the actual classifier.

Quality control and outlier analysis
Stringent quality control and outlier analysis was
performed on all datasets used for training and validation
to remove low quality arrays from the meta-analysis as
described in Supplementary Material and Methods.

Mapping of platform specific identifiers to entrez
gene IDs
To facilitate collation of the differentially expressed
genes identified by analysis of individual datasets, the
probe-level identifiers associated with each dataset were
annotated with corresponding gene-level identifiers
as described in detail in Supplementary Material and
Methods.

Pre-processing and normalization of microarray
datasets
Potential bias introduced by the range of
methodologies used in the original microarray studies,
including various experimental platforms and analytic
methods, was controlled by applying a uniform
normalization, preprocessing and statistical analysis
strategy to each dataset using the Frozen Robust Multiarray Average (fRMA) algorithm with rma background
www.impactjournals.com/oncotarget

Correlative laboratory evaluation
Antibodies, reagents, lentiviral production and
infection, cell culture, cell-based assays (proliferation,
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migration, invasion, soft agar growth), and Western blot
analysis are described in Supplementary Material and
Methods.
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